Viela Bio: • Developing novel therapies for wide range of autoimmune and severe inflammatory diseases, focusing on shared critical biological pathways to target underlying cause of disease
• Raised more than $172 million in recent IPO
• BLA for lead candidate, inebilizumab (anti-CD19 mAb), is under FDA review for the treatment of neuromyelitis optica spectrum disorder (NMOSD)—a rare condition that attacks the optic nerve, spinal cord and brain stem and often leads to irreversible blindness and paralysis—with a PDUFA date of June 11, 2020
• Company is preparing to initiate additional trials with inebilizumab in 2020, including in myasthenia gravis and IgG4-related disease
Based in...
US - South Atlantic
Clinical Stage
Phase III, Phase l or ll
Disease Space
Anti-inflammatory, Autoimmune
Public, USA
Market Cap
1B +
One MedImmune Way
Fifth Floor, Suite Area Two
Gaithersburg, MD 20878
United States

Company Participants at Boston Private Company Showcase

  • Zhengbin Yao, Ph.D, CEO

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2020 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.